Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prism Medico & PharmacyBOM:512217 +1.80%49 3-Year ROIIC % is 336.90 as of Mar. 2026, which is 1122900% above its 10-year median of 0.03. GuruFocus rates BOM:512217 with a GF Score™ of 49/100 and a GF Value™ of ₹9.35 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,838 Consumer Packaged Goods companies, Prism Medico & Pharmacy ranks better than 97.33% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Prism Medico & Pharmacy's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 336.90%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Prism Medico & Pharmacy's 3-Year ROIIC % or its related term are showing as below:
BOM:512217's 3-Year ROIIC % is ranked better than 97.33% of 1838
companies
in the Consumer Packaged Goods industry
Industry Median: 2.975
vs BOM:512217: 336.90
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Prism Medico & Pharmacy 3-Year ROIIC % Related Terms
Prism Medico & Pharmacy 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:512217 vs ADM, BG, TSN: 3-Year ROIIC % Comparison
For the Farm Products subindustry, Prism Medico & Pharmacy's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prism Medico & Pharmacy 3-Year ROIIC % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Prism Medico & Pharmacy's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Prism Medico & Pharmacy's 3-Year ROIIC % falls into.
Prism Medico & Pharmacy's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 3.016684 (Mar. 2026) - -0.7734776 (Mar. 2023) )
/
( 154.101 (Mar. 2026) - 152.976 (Mar. 2023) )
=
3.7901616
/
1.125
=
336.90%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Prism Medico & Pharmacy (BOM:512217) has a 3-Year ROIIC % of 336.90 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Prism Medico & Pharmacy and its competitors. This is 1122900% above median its historical median of 0.03. According to the industry distribution chart, Prism Medico & Pharmacy ranks #49 out of 1838 companies in the Consumer Packaged Goods industry, placing it in the top 2.7%.
Is Prism Medico & Pharmacy's 3-Year ROIIC % too high?
Prism Medico & Pharmacy's current 3-Year ROIIC % of 336.90 is 1122900% above median its 10-year median of 0.03. The Consumer Packaged Goods industry median 3-Year ROIIC % is 2.98. Prism Medico & Pharmacy's value of 336.90 is 11224.4% above this industry median. Based on the distribution chart, Prism Medico & Pharmacy ranks #49 out of 1838 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Prism Medico & Pharmacy has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prism Medico & Pharmacy's 3-Year ROIIC % compare to ADM and BG?
According to the Consumer Packaged Goods industry distribution chart, Prism Medico & Pharmacy ranks #49 out of 1838 companies for 3-Year ROIIC %. This places Prism Medico & Pharmacy in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 2.98. Prism Medico & Pharmacy's value of 336.90 is 11224.4% above this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 2.98, Prism Medico & Pharmacy has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Consumer Packaged Goods company?
The median 3-Year ROIIC % among Consumer Packaged Goods companies is 2.98, based on 1,838 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prism Medico & Pharmacy's current 3-Year ROIIC % of 336.90 is 11224.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Prism Medico & Pharmacy and its competitors. For the Consumer Packaged Goods industry, the median 3-Year ROIIC % is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prism Medico & Pharmacy's current 3-Year ROIIC % is 336.90, which is 1122900% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prism Medico & Pharmacy stock overvalued right now?
Based on GuruFocus' analysis, Prism Medico & Pharmacy (BOM:512217) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹9.35, compared to a current price of ₹29.41 — trading 214.5% above its estimated fair value. The current 3-Year ROIIC % is 336.90, which is 1122900% above median its 10-year median of 0.03 and 11224.4% above the Consumer Packaged Goods industry median of 2.98. Prism Medico & Pharmacy's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Prism Medico & Pharmacy (BOM:512217), the current 3-Year ROIIC % is 336.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prism Medico & Pharmacy (BOM:512217) Overvalued in 2026?
Based on GuruFocus' analysis, Prism Medico & Pharmacy stock appears to be overvalued.
The current stock price of ₹29.41 is trading 214.5% above its estimated GF Value™ of ₹9.35.
GuruFocus considers Prism Medico & Pharmacy to be Significantly Overvalued.
Key valuation signals for BOM:512217:
3-Year ROIIC %: 336.90 (1122900% above median its 10-year median of 0.03)
GF Value™: ₹9.35 vs. price of ₹29.41 (214.5% above fair value)
Industry Position: 11224.4% above the Consumer Packaged Goods median (#49 of 1838)
No single metric tells the full story. See the BOM:512217 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prism Medico & Pharmacy Ltd operates in the wholesale and retail of animal feed, poultry feed, cattle feed, aqua feed, ayurvedic foods, organic food, juices, cosmetics, herbal extracts, nutrients, and FMCG products. The company generates the majority of its revenue from the sale of agricultural products.
49GF Score
Get the complete analysis for BOM:512217
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:512217 has been successfully added to your 
